Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/11/2011

ted as of May 14, 2002 and previously amended on June 19, 2003, between the Company and OTC Corporate Transfer Service Company, as rights agent. The amendment increases the ownership threshold for determining "Acquiring Person" status under the Rights Agreement from 15%-18% and extends the "Final Expiration Date" for an additional two years, from May 31, 2012 to May 31, 2014.
  • In January 2011, the Company announced promising results from its study Chien-802, showing dramatic reductions in canine lipoma following injections with purified injectable collagenase. These results build upon an earlier dose escalation study from which the Company selected the dose for Chien-802.

  • In January 2011, the Company also announced the initiation of a larger clinical trial, Chien-803, for the same indication. On February 15, 2011, Auxilium filed a complaint against us in the Court of Common Pleas in Chester County, Pennsylvania.  We have voluntarily agreed to suspend this trial and will not be initiating any new trials using injectable collagenase in animals or humans pending a resolution of our dispute with Auxilium concerning our right to conduct clinical trials without the prior approval of the companies' Joint Development Committee.

  • In January 2011, Auxilium stated that it expects 2011 XIAFLEX U.S. net sales to be in the range of $50 million to $60 million.

  • In January 2011, Auxilium reported that, effective January 1, 2011, J0775 will be the code used to identify XIAFLEX when billed to Medicare, Medicaid and commercial health plans for reimbursement. The XIAFLEX specific CPT code is expected to be effective in January 2012.

  • In December 2010, the Company announced that The Journal of Hand Surgery published pivotal CORD II Phase III clinical trial of XIAFLEX.

  • In November 2010, the Company announced that it received a total of $426,000 in grant funding under the Qualifying Therapeutic Disco
    '/>"/>

  • SOURCE BioSpecifics Technologies Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
    2. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
    3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
    4. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
    5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
    6. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
    7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
    8. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
    9. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
    10. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
    11. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2015)... NEW YORK , August 27, 2015 ... on enhancing image processing functions in the human vision system, ... Angeles point guard Chris Paul to ... basketball players who want to improve their real-life on-court performance. ... on the court, whether it is shooting a ball or ...
    (Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
    (Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
    (Date:8/26/2015)... Florida , August 26, 2015 ... the biggest factors fueling the optimism in biotech,s ... M&A,s, collaborations and life sciences advancements.  Active biotechnology ... are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. ... SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
    Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
    ... 29 Pharmion Corporation,(Nasdaq: PHRM ) today ... has granted Fast Track designation for oral Azacitidine ... Track programs are designed to facilitate the development ... intended to treat serious or,life-threatening conditions and that ...
    ... with an overview of cardiovascular genetics ... ... 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN),a company focused on ... virtually any disease or medical,condition, today announced that its co-founder ...
    ... Aug. 29 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... specialty pharmaceutical and,medical device company, today announced ... has given clearance to begin marketing the,Hemo-Stream(TM) ... developed by Rex Medical, LP, is the ...
    Cached Biology Technology:Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6GeneNews' Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 2Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 3Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance 4
    (Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
    (Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
    (Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
    Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
    ... University of Bergen, Norway have deduced how bony fishes ... filling their eggs with the water of life ?the ... genes causes the eggs to fill with vital water ... extant marine teleosts that showed an unprecedented radiation during ...
    ... Scientists at the MIT Media Lab have invented a ... yellow light, offering the prospect of controlling the haywire ... and Parkinson's disease. , Such diseases often must be ... MIT research could lead to the development of optical ...
    ... , professor of molecular biophysics and biochemistry at ... Foundation to expand research on the delivery of a targeted ... and his collaborator Zhiwei Hu have developed a way to ... thus destroying the tumors while leaving normal tissue unharmed. ...
    Cached Biology News:How fish conquered the ocean 2How fish conquered the ocean 3MIT: Pulsing light silences overactive neurons 2Nanoparticles for delivery of prostate cancer treatment 2
    Request Info...
    ... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
    Preparation Note: by a modification of the procedure of C.W. Hancher et al., Biotechnol. Bioeng. 11, 1055 (1969) Assay: ~ 20 A 260 /mg Solubility: water 10 mg/mL, clear, light-yellow Suitab tst...
    Request Info...
    Biology Products: